TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01584271

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Natural Ear Comfort(TM), a botanical ear drops product
Description: Ear Comfort(TM): active ingredients - Thyme essential oil \& Camomile extract. Inactive ingredients: anhydrous glycerin and a small quantity of surfactant.~Dex-Otic(R): Dexamethasone sodium phosphate 1mg; neomycin sulfate 5mg; polymixin B sulfate 10,000 units.~Inactive ingredients: propylene glycol, sodium acetate anhydrous, phenyl mercuric acetate, purified water.~Otidin(R): Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin.
Study: NCT04104113

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Xiang Bei Yang Rong Tang
Description: Modified Xiang Bei Yang Rong Tang is a combination of 15 herbal components and it is available in granules form to be dissolved in hot water for consumption
Study: NCT04104113

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo granules contain 5% XBYRT, colourant, bitterant and 95% starch filler
Study: NCT01734772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: multiple doses of dabigatran
Study: NCT01584271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Natural Ear Comfort(TM), a botanical ear drops product
Description: Ear Comfort(TM): active ingredients - Thyme essential oil \& Camomile extract. Inactive ingredients: anhydrous glycerin and a small quantity of surfactant.~Dex-Otic(R): Dexamethasone sodium phosphate 1mg; neomycin sulfate 5mg; polymixin B sulfate 10,000 units.~Inactive ingredients: propylene glycol, sodium acetate anhydrous, phenyl mercuric acetate, purified water.~Otidin(R): Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin.
Study: NCT01001130

Intervention type: DRUG
Intervention: fluticasone furoate group
Description: patients who are administered fluticasone furoate at least once
Study: NCT03126214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulants
Description: Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with the Canadian Cardiovascular Society Guidelines for Atrial Fibrillation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulants
Description: Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with the Canadian Cardiovascular Society Guidelines for Atrial Fibrillation.
Study: NCT01422083

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: home stretching program
Description: A home stretching program (sleeper's stretch): 3 x 30 seconds, once a day for 6 weeks.
Study: NCT03834207

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of the C3-Cloud IT system
Description: Patients who are recruited to the intervention arm will use the C3-Cloud system during the pilot study.
Study: NCT00613223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib and Etoposide
Description: Vandetanib will be given orally once day. Swallow tablet with 240 ml of non-carbonated water. Initial dose is 100 mg/day for stratum 1 \& 200 mg/day for stratum 2. Etoposide will be taken by mouth in capsule form at a flat dose of 50 mg/day for 1st 21 days of 28-day cycle. You will not take etoposide for following 7 days of the cycle.
Study: NCT04522778

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearable Central Line Securement Device (Vest)
Description: The wearable central line securement device is a vest that has attachments for the central line to safely be secured to the body whether it is being used for infusion or unhooked. It also has a front flap, which protects the line from snagging on external objects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Securement Dressing
Description: All subjects will use sterile dressings throughout the trial as this is the standard of care for central line securement. Subjects randomized to the dressing arm will continue to use standard of care sterile dressing as the only form of central line securement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Securement Dressing
Description: All subjects will use sterile dressings throughout the trial as this is the standard of care for central line securement. Subjects randomized to the dressing arm will continue to use standard of care sterile dressing as the only form of central line securement.
Study: NCT01246219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GH treatment (Genotropin)
Description: 4 years treatment with GH

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 1 year treatment with placebo followed by optional 3 years of GH treatment
Description: 1 year treatment with placebo followed by optional 3 years of GH treatment
Study: NCT00160979

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pre-treatment tumour oxygen measurements
Description: Pre-treatment tumour oxygen measurements
Study: NCT01174485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exercise
Description: combined resistance and aerobic training
Study: NCT00177372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifepristone/misoprostol
Description: mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally
Study: NCT03935932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal delivery of heated and humidified air
Description: Subjects will receive nasal delivery of heated and humidified air (plus oxygen if needed) at 30 liters/minute from the Fisher and Paykel myAirvo2 heater/humidifier using an Optiflow nasal cannula.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasal delivery of heated and humidified air
Description: Subjects will receive nasal delivery of heated and humidified air (plus oxygen if needed) at 30 liters/minute from the Fisher and Paykel myAirvo2 heater/humidifier using an Optiflow nasal cannula.
Study: NCT01845311

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReZolve2 Scaffold
Study: NCT01664897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT00107081

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ciprofloxacin and amoxicillin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Outpatient management

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: i.v. antibiotics

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inpatient management
Study: NCT02723513

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperpolarized Xenon-129
Description: Hyperpolarized Xenon-129. Noble gas magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces.~Noble gas MRI provides a complimentary and alternative method for evaluating lung disease and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function.
Study: NCT01027663

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement
Description: Iron supplementation (325 mg of ferrous sulfate) once daily for the 2 month duration of the study.
Study: NCT01649037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nor adrenaline and terlipressin
Description: IV bolus terlipressin at the dose of 0.5 to 1 mg every 6 hours with the maximum daily cumulative dose of 4 mg/day.~Continuous IV infusion of NA starting at 0.5 mg/h with doubling of dose after every 4 hours in case of no response.\[ No response defined as MAP \< 10, or 4 hr Urine output \< 200 ml\] with maximum dose upto 3 mg/h.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: step up terlipressin therapy
Description: IV bolus terlipressin starting at 1.5 mg every 6 hours with increase in dose by 0.5 mg/6 hours in case of no response \[\< 25% decrease in s.creatinine\] after every 48 hours. Maximum daily cumulative dose of 12 mg/day.
Study: NCT00334971

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Follicle Aspiration
Description: Follicles will be aspirated using a transvaginal ultrasound guided needle.
Study: NCT01734772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: medium dose dabigatran

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: loading dose of ticagrelor
Study: NCT01537978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video gaming for enhanced function after spinal cord injury.
Description: Spinal cord injured indviduals will play Nintendo Wii sports games for an 8 week period.
Study: NCT00334971

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Follicle Aspiration
Description: Follicles will be aspirated using a transvaginal ultrasound guided needle.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Follicle Aspiration
Description: Follicles will be aspirated using a transvaginal ultrasound guided needle.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Follicle Aspiration
Description: Follicles will be aspirated using a transvaginal ultrasound guided needle.
Study: NCT02778906

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Administration of Abatacept s.c. 125mg/weekly according to the Label for Rheumatoid arthritis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of the comparator s.c. weekly in comparable to verum
Study: NCT04003961

Intervention type: OTHER
Intervention: STOP- BANG Questionnaire and Epworth sleepiness scale
Description: STOP- BANG Questionnaire and Epworth sleepiness scale will be filled in maximum 10 minutes

Intervention type: OTHER
Intervention: STOP- BANG Questionnaire and Epworth sleepiness scale
Description: STOP- BANG Questionnaire and Epworth sleepiness scale will be filled in maximum 10 minutes

Intervention type: OTHER
Intervention: STOP- BANG Questionnaire and Epworth sleepiness scale
Description: STOP- BANG Questionnaire and Epworth sleepiness scale will be filled in maximum 10 minutes
Study: NCT03691142

Intervention type: OTHER
Intervention: Questionnaire
Description: Interview of women with Hereditary Haemorrhagic Telangiectasia (HHT) during a consultation in the Reference Center for HHT or through a phone questionnaire about obstetric history, complications during pregnancy, delivery and neonatal outcomes.
Study: NCT02151071

Intervention type: DEVICE
Group type: OTHER
Intervention: EnLight
Description: The Lightpoint EnLight beta particle detector is an investigational non CE-marked medical device

Intervention type: DEVICE
Group type: OTHER
Intervention: LightPath
Description: The LightPath Imaging System is an investigational non CE-marked in vitro diagnostic device
Study: NCT02010983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chromoendoscopy
Description: chromoendoscopy (lugol stain and virtual chromoendoscopy)
Study: NCT00131547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary Counseling
Description: Dietary Counseling, use of a food diary and pedometer
Study: NCT03618212

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Skeletal MRI and pelvic and spinal MRI
Study: NCT00264823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of Memory Aids to take medications
Description: Experimental participants will receive an integrated intervention tailored to the communication and comprehension of the individual, and will include memory aid devices, education regarding side effects and other treatment aspects, and active community outreach. For those who fail to adhere using the basic intervention, a treatment cascade that increases in intensity will be implemented. Using 80% adherence as a target, the cascade will include involvement of family and significant others in prompting participants through use of beepers, cellphones, and for those who still fall short of 80% adherence, directly observed therapy.
Study: NCT02196168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study: NCT01734772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: multiple doses of ticagrelor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: loading dose of ticagrelor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: single dose of dabigatran
Study: NCT02034331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin iontophoresis
Description: For insulin iontophoresis, the cathode electrode will contain 0.2 ml of liquid insulin. For preparation and instrumentation, the arms will be uncovered below the elbow; the participant's lower extremities will be uncovered below knee for leg evaluations. The laser Doppler flowmetry (LDF) lead will be placed bilaterally, 2 inches proximal to the lateral malleolus over the peroneus longus muscle. For arm evaluations, a lead will be placed (and secured with dual-sided transparent tape) bilaterally, 2 inches distal to the lateral epicondyle over the flexor carpi ulnaris muscle along the midline with the ulnar process. Baseline and peak cutaneous blood flow responses to application of insulin iontophoresis will be determined for each LDF lead during the evaluation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Iontophoresis
Description: For placebo iontophoresis, the cathode electrode will contain 0.2 ml of preservative-free normal saline; the anode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcholine Iontophoresis
Description: For acetylcholine iontophoresis, the anode electrode will contain 0.2 ml of 1% acetylcholine chloride; the cathode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Heat application
Description: For the provocation with heat, an insulated thermal heat pack (\~106°F) will be applied to the exposed arm or leg for 18 minutes. The thermal heat pack is comparable to what is routinely used as a heat therapy in conventional rehabilitation settings. LDF leads and temperature sensors will be placed in the previously specified locations to evaluate the changes.
Study: NCT02281578

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-based combination HIV prevention intervention
Description: The combination package will include integrated biomedical, behavioral and structural components: (1) mobile HIV testing and risk reduction counseling; (2) service navigation to facilitate access to treatment and retention in care; (3) sensitivity training for HIV clinical care providers; (4) SMS text messages to promote adherence to care and ART; (5) venue-based peer education and condom distribution; and (6) a community drop-in-center to promote cohesion and collective action to reduce stigma and discrimination.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care HIV services
Description: Locally available standard of care HIV prevention, treatment and care services
Study: NCT01912105

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airway medix closed suction system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard closed suctioning systems
Study: NCT03185897

Intervention type: OTHER
Intervention: Non-treatment, seroprevalence
Description: Non-treatment study examining the prevalence of preexisting immunity to adeno-associated virus (AAV)
Study: NCT02196168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WEE1 Inhibitor AZD1775
Description: Given PO
Study: NCT00634218

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mail-based Self-help plus Internet-based Smoking Treatment
Description: Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Manual plus Telephone counseling
Description: Participants will receive a self-help manual specifically developed for LGBT smokers plus 6 telephone-based counseling sessions. The counseling sessions focus on the development of a personalized plan to quit smoking and occur over a 3 month period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Manual
Description: Participants will receive a self-help smoking cessation manual specifically developed for LGBT smokers. The manual provides information on quitting smoking and encourages the development of a personalized quit plan through various activities and exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Manual plus Internet-based Intervention plus Telephone Counseling
Description: Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants. Smokers will also receive 6 telephone-based counseling sessions which occur over a 3 month period
Study: NCT00998829

Intervention type: OTHER
Intervention: questionnaire
Description: There is no therapeutic intervention in this study. However PASE (Psoriatic Arthritis Screening and Evaluation) and other patient questionnaires will be completed by participants.
Study: NCT03142828

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Healing abutment with Clorhexidine

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Healing abutment without any antiseptic
Study: NCT01916798

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid infusion
Description: IV infusion of 250 ml of intralipid 20% solution at the day of Ovum pick up \& another dose at the day of embryo Transfer.
Study: NCT05566509

Intervention type: PROCEDURE
Intervention: Breast excision
Description: some patient had minimal excision, some had maximal excision.

Intervention type: PROCEDURE
Intervention: Breast excision
Description: some patient had minimal excision, some had maximal excision.
Study: NCT01729923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo stereotactic radiosurgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgical resection
Study: NCT01252511

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RYGB for surgical treatment of severe obesity
Description: Twenty severely obese patients who have been scheduled to receive long limb RYGB will be enrolled in the study. By randomization, 10 patients will have a biliopancreatic limb that includes 40 cm of jejunum and a Roux limb that contains 150 cm of jejunum. The other 10 patients will receive a biliopancreatic limb that contains 75 cm of jejunum and a Roux limb of 115 cm.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RYGB for surgical treatment of severe obesity
Description: Twenty severely obese patients who have been scheduled to receive long limb RYGB will be enrolled in the study. By randomization, 10 patients will have a biliopancreatic limb that includes 40 cm of jejunum and a Roux limb that contains 150 cm of jejunum. The other 10 patients will receive a biliopancreatic limb that contains 75 cm of jejunum and a Roux limb of 115 cm.
Study: NCT01993576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: Intravenous injection of 0.25 mg/kg Indocyanine Green (ICG) before the surgery
Study: NCT00812123

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Loading dose 30 mg for three days, trough level of 10-20 ng/ml month 1-3, 8-15 ng/ml month 4 - 6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine A
Description: Loading dose of 300 mg for three days, trough levels 250-300 ng/ml months 1-3, 150-250 ng/ml months 4 to 6

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 0.5 mg/kg, tapering every two weeks until 0.1 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 0.5 mg/kg, tapering every two weeks until 0.1 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: 2 x 1000mg, through level above 2ug/ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: 2 x 1000mg, through level above 2ug/ml

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Protocol biopsies
Description: protocol kidney biopsies at month one and three

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Protocol biopsies
Description: protocol kidney biopsies at month one and three
Study: NCT01090700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 150 mg daily for 7 days

Intervention type: DRUG
Group type: OTHER
Intervention: Escitalopram
Description: Escitalopram 10 mg daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435 + Escitalopram
Description: TMC435 150 mg + escitalopram 10 mg daily for 7 days